Company profile: Cavion
1.1 - Company Overview
Company description
- Provider of clinical-stage therapies targeting T-type calcium channels (Cav3) for cancer and neurologic diseases, including CX-8998, a modulator in Phase 2 for essential tremor and absence epilepsy, and Mibefradil, a partially selective blocker tested with hypofractionated radiation in recurrent glioblastoma multiforme.
Products and services
- Cav3-Selective Drug Development Program: Engineers mechanism-specific therapies that selectively inhibit T-type calcium channels (Cav3) for neurologic diseases and solid tumor cancers, leveraging ion channel targeting for treatment
- CX-8998: A clinical-phase T-type calcium channel (Cav3) modulator investigated in Phase 2 trials for essential tremor and absence epilepsy
- Mibefradil: A combination-therapy, partially selective T-type calcium channel blocker tested with hypofractionated radiation therapy for recurrent glioblastoma multiforme
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Cavion
Bioinduction
HQ: United Kingdom
Website
- Description: Provider of faster and simpler deep brain stimulation.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Bioinduction company profile →
Kineta
HQ: United States
Website
- Description: Provider of biotechnology drug discovery focused on diseases caused by protein misfolding, offering immunotherapies such as KVA12123, a VISTA-blocking agent in Phase 1/2 trials as monotherapy and with pembrolizumab, and an anti-CD27 agonist mAb to activate T and NK cells and address exhausted T cells in the tumor microenvironment.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Kineta company profile →
Iama Therapeutics
HQ: Italy
Website
- Description: Provider of novel neuroscience therapeutics for pediatric brain disorders, advancing drug discovery to address unmet needs; lead candidate IAMA-6 is an orally administered small molecule targeting NKCC1-associated neuronal hyperexcitability, currently in Phase 1 clinical trials for autism and epilepsy.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Iama Therapeutics company profile →
Javelin Pharmaceuticals
HQ: United States
Website
- Description: Provider of specialty pharmaceutical research, development, and commercialization of products for the pain management market primarily in the United States and Europe, focusing on treatments for various pain disorders ranging from acute and episodic moderate-to-severe pain.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Javelin Pharmaceuticals company profile →
Bonti
HQ: United States
Website
- Description: Provider of biotechnology, based in Orange, California. Founded in 2015 by Fauad Hasan, Mike Jarpe, Susan Abushakra, and Wajdie Ahmad.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Bonti company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Cavion
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Cavion
2.2 - Growth funds investing in similar companies to Cavion
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Cavion
4.2 - Public trading comparable groups for Cavion
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →